PCM
SLS icon

Prelude Capital Management’s SELLAS Life Sciences SLS Stock Holding History

Prelude Capital Management’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-58,338
Closed -$72.9K – 1535
2024
Q3 		$72.9K Buy
58,338
+2,612
+5% +$3.19K ﹤0.01% 1186
2024
Q2 		$66.3K Buy
+55,726
New +$75.8K ﹤0.01% 1134
2022
Q2 		– Sell
-31,125
Closed -$208K – 2037
2022
Q1 		$208K Buy
+31,125
New +$182K 0.01% 1250
2017
Q3 		– Hold
0
– – – 1882
2017
Q2 		– Sell
-5
Closed -$4.35K – 1824
2017
Q1 		$5K Buy
+5
New +$8.28K ﹤0.01% 1411

Other funds holding SLS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Prelude Capital Management's SLS Position: Q4 2024 in Review

Prelude Capital Management sold out of SELLAS Life Sciences (SLS) in Q4 2024, closing a stake of 58,338 shares — an estimated $72.9K sold.

Prelude Capital Management first reported a position in SLS in Q1 2017 and held it in 4 quarters. The position peaked at $208K in Q1 2022. 31 funds tracked by Wall St. Rank hold SLS as of Q4 2024.

  • Prelude Capital Management reported no remaining SELLAS Life Sciences position as of Q4 2024 after selling out during the quarter.
  • Prelude Capital Management sold 58,338 SELLAS Life Sciences shares in Q4 2024, an estimated $72.9K.
  • Prelude Capital Management first reported a position in SELLAS Life Sciences in Q1 2017 and held it in 4 quarters.
  • Prelude Capital Management's SELLAS Life Sciences position peaked at $208K in Q1 2022.
  • 31 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q4 2024.

Based on Prelude Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.